Qiagen expands digital PCR oncology research portfolio

QIAGEN (QGEN) “announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications. The combination of QIAGEN’s global reach and automation expertise with the assay development and manufacturing capabilities of ID Solutions will strengthen QIAGEN’s position in oncology research. Under the agreement, ID Solutions will manufacture and supply dPCR assays for non-clinical research use on QIAGEN’s QIAcuity platforms. These assays are optimized to simultaneously detect multiple mutations in cell-free DNA from plasma and genomic DNA from formalin-fixed, paraffin-embedded tissue. QIAGEN will commercialize these kits starting in Europe as the first region, with the potential for future expansion into other regions.”